Ride2Work Day: What role has intellectual property played in the success of the Brompton folding bike?
It’s that time of the year again: it’s National Ride2Work Day (Wednesday 17 October 2018). With this in mind, I thought I’d take the opportunity to show my appreciation for my favourite way to travel to work: the Brompton folding bicycle. I take a brief look at the bike and the role of intellectual property
A strong IP strategy is a vital part of any business, especially in the resources sector where innovation has historically provided key competitive advantages Dr Michael Zammit, and Scott Philp, Shelston IP Senior Associates, provide insights into the strategic role of IP for entities operating in the resources sector. To read the full article,
The “CPTPP”, otherwise known as the Comprehensive and Progressive Agreement for Trans-Pacific Partnership is what remains of the “TPPA-11” (which was itself, what remained of the Trans-Pacific Partnership (“TPP”) Free Trade Agreement following the withdrawal of the United States). Earlier today (8 March 2018), in Santiago, Chile, the eleven remaining signatories put pen to paper
Did you know that a European patent application can be used to secure protection reaching beyond the EPC member states? Perhaps surprisingly, a European patent application can be used to obtain protection in other territories – including some geographically remote from Europe. This article summarises relevant information about extension states, validation states and requesting protection
Following on from recent Patent Office success in court in rejecting Business Method Patents, the Patent Office has released new guidelines on the patentability of computer implemented inventions. Whilst the court authorities are presently on appeal, the Office is proceeding to issue the guidelines to align practices with their preferred position, which was adopted
Shelston IP was pleased to sponsor the University of Sydney’s inaugural pharmaceutical industry engagement event, which took place on 26 May 2015. In attendance were more than 100 of the University’s top academics from within the chemical, pharmaceutical and life sciences disciplines – along with representatives of industry and government. The aim of the